Automated, intelligent oral contraception prescribing via telemedicine - using AI to improve patient health outcomes and streamline time-intensive assessment processes, exacerbated by COVID-19

新型冠状病毒肺炎证实并加剧了提高效率的必要性（在NHS长期计划中确定）通过紧急引入自动化和在可行的情况下利用远程医疗来减少资源压力，特别是在第二波/未来高峰即将到来的前景下。Covid-19的持续影响意味着超过45%的非紧急预约被取消或推迟，使得全科医生积压了大量工作避孕和口服避孕药（OC）处方是访问全科医生（英国）的第二大最常见原因，每年约有2000多万次预约，相当于13，900天，被归类为“非紧急”。“54%的性健康诊所关闭，年轻女性经常利用这些诊所进行避孕咨询，使许多人得不到支持，这进一步加剧了这一问题。NHS长期/NIHR后新冠肺炎战略中确定的智能自动化技术可以在这方面有所帮助，特别是当与最近策划的关于荷尔蒙分布的大型女性健康数据集相结合时。减少对全科医生诊所的需求，同时通过确保首次处方的最佳可用药物来改善处方流程（52%的用户在第一次处方药物时会出现副作用，平均需要再进行2次咨询，以管理不良副作用并确定最佳药物）。基于我们的CE认证激素健康平台和原型TRL 5患者分层算法，我们打算开发和跟踪（与NHS合作伙伴CNWL NHS信托基金一起）为女性避孕治疗提供新的远程医疗平台，* 自动化会诊和分诊流程 * 通过患者分层智能/准确地选择最佳可用OC（利用先进的算法），考虑到一个女人的独特的激素谱 * 持续的远程推广和监测，由我们的数字支持中心-\>早期检测的副作用，通过咨询/指导/在必要时改变药物来缓解。**影响 ** 该项目既解决了目前处方方法的长期低效，也解决了COVID-19对全科医生/初级保健的直接影响。该技术将明确;1。通过远程分诊，在70%的病例中无需全科医生：每年节省约9730个全科医生工作日。2.通过我们CE认证的GP知识库，改进剩余30%复杂病例的分诊流程。3.通过人工智能辅助患者分层提高药物处方的准确性，减少约60%的重新咨询。4.通过我们的合作伙伴Pharmacy 2U和Mayberry\_Pharmacy5启用远程处方。帮助减少NHS激素药物相关副作用的成本约19亿英镑（NHS：2019）6。通过数字化外展和互动改善患者护理和主动管理。7.可以在全国范围内大规模快速推广。

Covid 19 has validated and compounded the need for improved efficiencies (identified within the NHS Long Term plan) via the urgent introduction of automation and the utilisation of Telemedicine where feasible to reduce strain on resources, especially with the prospect of a second wave/future spikes on the horizon.The ongoing impact of Covid-19 meant over 45% of non-urgent appointments were either cancelled or postponed, leaving GP's with significant backlogs. Contraception and prescription of Oral Contraceptives (OC) is the second most common reason to visit a GP (UK), accounting for more than 20m appointments/annum, equivalent to 13,900 days and is classed as "non-urgent."This has been further compounded by the closure of 54% of Sexual Health Clinics, often utilised by young females for contraceptive consultations, leaving many unsupported.Intelligent, automated technology, as identified in the NHS Long-Term/NIHR post-Covid strategies, can help in this regard in particular when combined with recently curated large female health datasets on hormonal profiles. Reducing demand on GP clinics whilst improving the prescribing process by ensuring optimum available medication is prescribed first time (52% of users suffer side-effects on the first prescribed medication, on average resulting in 2 further consultations to manage adverse side-effects and determine optimum medication).Building upon our CE-Marked hormonal health platform and prototype TRL5 patient stratification algorithms, we intend to develop and trail (alongside NHS partner CNWL NHS Trust) a new Telemedicine platform for female contraceptive treatments that will;* Automate the consultation and triage process* Intelligently/accurately select the optimum available OC via patient stratification (utilising advanced algorithms) that considers a woman's unique hormone profile* Ongoing remote outreach and monitoring by our digital support hub-\> earlier detection of side-effects, mitigation through counselling/coaching /medication changes where warranted.**Impact**The project addresses both a long-term inefficiency in the current prescribing method, as well as addresses the immediate impact of COVID-19 on GPs/Primary Care. The technology will explicitly;1. Remove the need for a GP in 70% of all cases via remote triage: saving ~9730 GP-days/annum.2. Improve the triage process for remaining 30% of complex cases via our CE-Marked knowledge base for GPs.3. Improve the accuracy of medication prescription through AI-assisted patient stratification, reducing re-consultations by ~60%.4. Enable remote prescribing via our partners Pharmacy2U&Mayberry\_Pharmacy5. Help reduce the ~£1.9Bn cost to the NHS of hormonal medication related side-effects(NHS:2019)6. Improve patient care and proactive management through digital outreach and interaction.7. Can be rolled out nationally, at scale, quickly.